Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis

Medical Journal of Australia

Volumn 187, Issue 9, 2007, Pages 524-526

  Ozorio, Gerard ^a   McGarity, Bruce ^b   Bak, Haesung ^c   Jordan, Andrew A ^c   Lau, Henry ^d   Marshall, Cathy ^e  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b Western NSW Local Health District   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d Orange Hospital   (Australia)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; LEFLUNOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABNORMAL FECES; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE HEPATITIS; BACKACHE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; JAUNDICE; LIVER BIOPSY; LIVER DISEASE; LIVER NECROSIS; SIDE EFFECT; BIOPSY; DRUG ANTAGONISM; LIVER; LIVER FUNCTION TEST; MIDDLE AGED; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOPSY; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER; LIVER FUNCTION TESTS; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38449123106     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2007.tb01396.x     Document Type: Article

References (10)

1. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
2. Tobon G, Cañas C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol 2007; 26: 578-581.
3. United States Food and Drug Administration. Safety alerts for drugs, biologics medical devices, and dietary supplements. Remicade (infliximab). Washington, DC: FDA, 2004. http://www.fda.gov/medwatch/ SAFETY/2004/safety04.htm#Remicade2 (accessed Sep 2007).
4. Everitt DE. Centocor. Important drug warning. December 2004. http://www.fda.gov/medwatch/SAFETY/2004/remicade_DHCP_dec04.pdf (accessed Sep 2007).
5. Saleem G, Li SC, MacPherson BR, Cooper SM. Hepatitis with interface inflammation and IgG, IgM and IgA anti double stranded DNA antibodies following infliximab therapy. Arthritis Rheum 2001; 44: 1966-1968.
6. Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005; 64: 1519-1520.
7. Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Autoimmun Rev 2003; 2: 241-247.
8. Diamantis I, Boumpas DT. Autoimmune hepatitis: evolving concepts. Autoimmun Rev 2004; 3: 207-214.
9. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF-alpha. Ann Rheum Dis 2005; 64: 403-407.
10. Charles PJ, Smeenk RJT, De Jong J, et al. Assessment of antibodies to double stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumour necrosis factor alpha: findings in open label and randomised placebo controlled trials. Arthritis Rheum 2000; 43: 2383-2390.